These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23430741)

  • 1. Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.
    Bhattacharyya S; Singh P; Rathore U; Purwar M; Wagner D; Arendt H; DeStefano J; LaBranche CC; Montefiori DC; Phogat S; Varadarajan R
    J Biol Chem; 2013 Apr; 288(14):9815-9825. PubMed ID: 23430741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles.
    Purwar M; Pokorski JK; Singh P; Bhattacharyya S; Arendt H; DeStefano J; La Branche CC; Montefiori DC; Finn MG; Varadarajan R
    Vaccine; 2018 Oct; 36(42):6345-6353. PubMed ID: 30220462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.
    Bhattacharyya S; Rajan RE; Swarupa Y; Rathore U; Verma A; Udaykumar R; Varadarajan R
    J Biol Chem; 2010 Aug; 285(35):27100-27110. PubMed ID: 20558728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
    Falkowska E; Ramos A; Feng Y; Zhou T; Moquin S; Walker LM; Wu X; Seaman MS; Wrin T; Kwong PD; Wyatt RT; Mascola JR; Poignard P; Burton DR
    J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
    Ahmed FK; Clark BE; Burton DR; Pantophlet R
    Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
    Pantophlet R; Ollmann Saphire E; Poignard P; Parren PW; Wilson IA; Burton DR
    J Virol; 2003 Jan; 77(1):642-58. PubMed ID: 12477867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
    Gnanakaran S; Daniels MG; Bhattacharya T; Lapedes AS; Sethi A; Li M; Tang H; Greene K; Gao H; Haynes BF; Cohen MS; Shaw GM; Seaman MS; Kumar A; Gao F; Montefiori DC; Korber B
    PLoS Comput Biol; 2010 Oct; 6(10):e1000955. PubMed ID: 20949103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
    Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
    J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.
    Herrera C; Spenlehauer C; Fung MS; Burton DR; Beddows S; Moore JP
    J Virol; 2003 Jan; 77(2):1084-91. PubMed ID: 12502824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
    Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
    J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site.
    Burioni R; Mancini N; De Marco D; Clementi N; Perotti M; Nitti G; Sassi M; Canducci F; Shvela K; Bagnarelli P; Mascola JR; Clementi M
    PLoS One; 2008; 3(10):e3423. PubMed ID: 18923648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
    Pantophlet R; Wilson IA; Burton DR
    Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design.
    Saha P; Bhattacharyya S; Kesavardhana S; Miranda ER; Ali PS; Sharma D; Varadarajan R
    Biochemistry; 2012 Mar; 51(9):1836-47. PubMed ID: 22329717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.